3rd Annual Jefferson Urology Symposium: Men’s Health Forum

© The Canadian Journal of Urology TM : International Supplement, August 2020 Conclusions Minimally invasive surgical therapy is becoming a popular alternative to TURP or other more definitive prostate reducing procedures. Aquablation, Rezum, and Urolift are procedures that are currently approved by the AUA guidelines for the surgical management of BPH for patients with prostate sizes less than 80 grams. While PAEmay be effective in treating LUTS by reducing prostate size, it is considered investigational by the current AUA guidelines. Aquablation, Rezum, and Urolift are surgical treatment options capable of providing rapid, significant, and durable relief of LUTS secondary to BPH. Rezum and Urolift procedures offer a distinct advantage over Aquablation since it can be performed in an office or an outpatient setting. Current AUAguidelines recommend each therapy for use in select patient populations. When performed in the appropriate patient, each therapy has been shown to have comparable or superior efficacy to TURP with the added advantage of preserving sexual function and decreasing patient morbidity and healthcare costs. It is important to counsel patients on all interventional options, considering prostate size and anatomy, sexual function, symptom severity, and patient expectations in order to provide successful individualized care. As urologists continue to investigate established and novel BPH treatments, the landscape for surgical BPH management will continue to evolve, providing unique opportunities for enhanced patient care. References 1. Chung ASJ, Woo HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J Urol 2018;5(1):22-27. 2. Ray AF, Powell J, Speakman MJ et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int 2018;122(2):270-282. 3. Zumstein V, Betschart P, Vetterlein MW et al. Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus 2019;5(6):1091-1100. 4. Pisco JM, Bilhim T, Costa NV et al. Randomised clinical trial of prostatic artery embolisation versus a sham procedure for benign prostatic hyperplasia. Eur Urol 2020;77(3):354-362. 5. Foster HE, Dahm P, Kohler TS et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2019. J Urol 2019;202(3):592-598. 6. Faber K, de Abreu AL, Ramos P et al. Image-guided robot- assisted prostate ablation usingwater jet-hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. J Endourol 2015;29(1):63-69. 7. Taktak S, Jones P, Haq A, Rai BP, Somani BK. Aquablation: a novel and minimally invasive surgery for benign prostate enlargement. Ther Adv Urol 2018;10(6):183-188. 8. MacRae C, Gilling P. How I do it: Aquablation of the prostate using theAQUABEAM system. Can J Urol 2016;23(6):8590-8593. 9. Gilling P, Barber N, Bidair M et al. WATER: a double-blind, randomized, controlled trial of Aquablation. J Urol 2018;199(5): 1252-1261. 10. Plante M, Gilling P, Barber N et al. Symptom relief and anejaculation afterAquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU Int 2019;123(4):651-660. 11. Gilling P, Barber N, Bidair M et al. Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol 2020;27(1):10072-10079. 12. Desai M, Bidair M, Bhojani N et al. WATER II (80-150 mL) procedural outcomes. BJU Int 2019;123(1):106-112. 13. Desai M, Bidair M, Zorn KC et al. Aquablation for BPH in large prostates (80-150 cc): 6-month results from the WATER II trial. BJU Int 2019;124(2):321-328. 14. Bhojani N, Bidair M, Zorn KC et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 1-year results. Urology 2019;129:1-7. 15. Nguyen DD, Barber N, Bidair M et al. Waterjet ablation therapy for endoscopic resection of prostate tissue trial (WATER) vs. WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30-80 and 80-150 mL prostates. BJU Int 2020;125(1):112-122. 16. Elterman D, Bach T, Rijo E et al. Transfusion rates after 800 AquablationR procedures using various haemostasis methods. BJU Int 2020;125(4):568-572. 17. Nair SM, Pimentel MA, Gilling PJ. Evolving and investigational therapies for benign prostatic hyperplasia. Can J Urol 2015; 22(Suppl 1):82-87. 18.Mynderse LA, Hanson D, Robb RA et al. Rez ū m system water vapor treatment for lower urinary tract symptoms/ benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology 2015;86(1): 122-127. 19. DixonCM,RijoCedanoE,MynderseLA,LarsonTR.Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rez ū m system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol 2015;7:13-18. 20. McVary KT, Gange SN, GittelmanMC et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2016;195(5):1529-1538. 21. Roehrborn CG, Gange SN, Gittelman MC et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 2017;197(6):1507-1516. 22. McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rez ū m system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology 2018;111:1-9. 9 Benign prostatic hyperplasia: an update on minimally invasive therapy including Aquablation